Citigroup Boosts Danaher (DHR) Price Target to $107.00
DHR has been the subject of a number of other reports. Morgan Stanley upped their price target on shares of Danaher from $95.00 to $98.00 and gave the company an overweight rating in a report on Friday, October 20th. Credit Suisse Group increased their target price on shares of Danaher from $93.00 to $96.00 and gave the company an outperform rating in a research note on Friday, October 20th. Zacks Investment Research upgraded shares of Danaher from a hold rating to a buy rating and set a $97.00 target price for the company in a research note on Thursday, October 5th. Goldman Sachs Group reiterated a neutral rating and issued a $83.00 target price on shares of Danaher in a research note on Tuesday, September 26th. Finally, Robert W. Baird increased their target price on shares of Danaher from $87.00 to $97.00 and gave the company an outperform rating in a research note on Friday, October 20th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of Buy and a consensus price target of $94.05.
Shares of Danaher (NYSE:DHR) opened at $94.00 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.00 and a debt-to-equity ratio of 0.42. Danaher has a fifty-two week low of $77.66 and a fifty-two week high of $94.82. The stock has a market cap of $65,386.87, a PE ratio of 24.16, a price-to-earnings-growth ratio of 2.24 and a beta of 1.02.
The business also recently announced a quarterly dividend, which will be paid on Friday, January 26th. Investors of record on Friday, December 29th will be paid a $0.14 dividend. This represents a $0.56 annualized dividend and a dividend yield of 0.60%. The ex-dividend date is Thursday, December 28th. Danaher’s payout ratio is presently 16.52%.
In related news, SVP Daniel Raskas sold 37,870 shares of the stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $93.33, for a total value of $3,534,407.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Robert S. Lutz sold 11,189 shares of the stock in a transaction dated Monday, October 23rd. The stock was sold at an average price of $91.66, for a total transaction of $1,025,583.74. Following the completion of the transaction, the chief accounting officer now directly owns 18,314 shares of the company’s stock, valued at approximately $1,678,661.24. The disclosure for this sale can be found here. Insiders sold 273,810 shares of company stock valued at $25,218,813 in the last three months. Company insiders own 12.20% of the company’s stock.
A number of large investors have recently bought and sold shares of DHR. GQG Partners LLC acquired a new stake in shares of Danaher during the second quarter worth approximately $101,000. Zions Bancorporation increased its holdings in shares of Danaher by 118.3% during the third quarter. Zions Bancorporation now owns 1,231 shares of the conglomerate’s stock worth $106,000 after buying an additional 667 shares in the last quarter. Patten Group Inc. increased its holdings in shares of Danaher by 262.3% during the third quarter. Patten Group Inc. now owns 4,830 shares of the conglomerate’s stock worth $114,000 after buying an additional 3,497 shares in the last quarter. Monetary Management Group Inc. increased its holdings in shares of Danaher by 10.7% during the second quarter. Monetary Management Group Inc. now owns 1,550 shares of the conglomerate’s stock worth $131,000 after buying an additional 150 shares in the last quarter. Finally, Acrospire Investment Management LLC increased its holdings in shares of Danaher by 185.5% during the second quarter. Acrospire Investment Management LLC now owns 1,693 shares of the conglomerate’s stock worth $143,000 after buying an additional 1,100 shares in the last quarter. 76.32% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This article was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://www.watchlistnews.com/citigroup-boosts-danaher-dhr-price-target-to-107-00/1770733.html.
Danaher Company Profile
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.